Spironolactone

CHEMBL1393 Phase 4 Approved Small molecule
Half-Life
1.4 hours
Bioavailability
Protein Binding
Molecular Weight
416.6 g/mol
LogP
2.9
Phase
4

By antagonizing the mineralocorticoid receptor, spironolactone opposes aldosterone, the hormone that signals the kidney to retain sodium and excrete potassium. Blocking that signal makes it a potassium-sparing diuretic: it removes excess fluid and sodium while conserving potassium, easing the strain of fluid overload in heart failure and lowering blood pressure. Because it also blunts androgen activity, it is widely used for hormone-driven conditions including polycystic ovary syndrome and as an anti-androgen in hormone therapy. A steroidal small molecule (C24H32O4S) with a short parent half-life near 1.4 hours, its effect is prolonged by active metabolites. This combination of diuretic and anti-androgen properties gives it an unusually broad range of uses. Spironolactone is an approved medicine spanning cardiology and endocrinology.

This aldosterone-blocking diuretic removes excess fluid and sodium from the body while sparing potassium, reducing the strain of fluid overload on the heart and blood vessels. Beyond heart failure and hypertension, it is widely used for hormonal conditions including polycystic ovary syndrome and as an anti-androgen in hormone therapy.

Molecular Weight

416.5740 g/mol

LogP

2.90

TPSA

85.70 Ų

Lipinski RO5

Pass

Therapeutic Areas

Drug Classes

Mechanism of Action

Mineralocorticoid receptor antagonist.

Pharmacokinetics (PK)

Half-Life 1.4 hours

Pharmacodynamics (PD)

Mechanism

Mineralocorticoid receptor antagonist.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12

InChI

InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

Molecular Formula

C24H32O4S

HBD / HBA

- / 5

Rotatable Bonds

2

Heavy Atoms

29

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This aldosterone-blocking diuretic removes excess fluid and sodium from the body while sparing potassium, reducing the strain of fluid overload on the heart and blood vessels. Beyond heart failure and hypertension, it is widely used for hormonal conditions including polycystic ovary syndrome and as an anti-androgen in hormone therapy.

Mineralocorticoid receptor antagonist.

Key pharmacokinetic parameters for Spironolactone: Half-life: 1.4 hours.

Yes, Spironolactone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1393. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5833. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.